Image pharmaphorum Editor Oncology Diversity by design: the importance of DE&I in oncology tria... “First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients. Oncology Immunotherapy: building the fourth pillar of cancer treatmen... Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation. Views & Analysis Digital tools driving innovative clinical trials The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the cl Oncology Deep Dive: Oncology 2022 Eradicating cancer is an ambitious goal for oncologists and life science companies around the world. Load more results
Oncology Diversity by design: the importance of DE&I in oncology tria... “First, do no harm”; is an ethical axiom at the heart of medical research; physicians worldwide pledge to uphold the oath to serve patients.
Oncology Immunotherapy: building the fourth pillar of cancer treatmen... Cancer treatment has been traditionally characterised by surgery, chemotherapy, and radiation.
Views & Analysis Digital tools driving innovative clinical trials The COVID-19 pandemic has catalysed significant changes in the way pharma develops drugs, particularly in the cl
Oncology Deep Dive: Oncology 2022 Eradicating cancer is an ambitious goal for oncologists and life science companies around the world.
Patients Precision medicine in action, with Cary Claiborne Cary Claiborne, CEO of Adial Pharmaceuticals, discusses his company’s bet on a precision treatment for AUD.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
